Lisa Swanson, MD: Detailing Infantile Hemangioma
Though not all hemangioma last past 10 years old in pediatric patients, some untreated hemangioma are associated with high risk of ulceration.
Saakshi Khattri,MD: Evolving Therapies for Psoriatic Disease
Though Dr. Khattri felt the diagnosis of psoriatic arthritis had been “stagnant”, the inclusion of biologic therapies and more has been a welcomed change.
Boni Elewski, MD: Safety and Efficacy of New Psoriasis Therapies
Certain biologics such as infliximab have aided psoriasis patients in the mitigation of symptoms from the COVID-19 virus.
Lisa Swanson, MD: The Psychology of Pediatric Chronic Skin Conditions
Dr. Swanson also details the effects of the COVID-19 pandemic on her practice with the implementation of telemedicine.
Seemal Desai, MD: The Promise of JAK Inhibitors in Vitiligo Management
Dr. Desai says that Janus kinase inhibitors present a new mechanism of action, with effects on cytokine signals that signal inflammation in atopic diseases.
Boni Elewski, MD: The Future of Psoriasis Therapy
Dr. Elewski speaks of the safety and efficacy of several new and developing therapies, including bimekizumab treatment which has yet to be approved in the United States.
Lisa Swanson, MD: Detailing Therapies for Pediatric Skin Conditions
Swanson noted the efficacy and safety of dupilumab, which she feels revolutionized patient care.
Saakshi Khattri, MD: Diagnosing Psoriatic Arthritis Early in Psoriasis Patients
Dr. Khattri speaks of the benefits of diagnosing the condition early in psoriasis patients, as well as what dermatologists can do before referring a patient to a rheumatologist.
Seemal Desai, MD: Advancements in Vitiligo Therapies
New therapies are breaking ground in the world of vitiligo research, which Dr. Desai believes will result in FDA approvals in the coming years.